Catalog No.
Product Name
Application
Product Information
Citations
-
COX Inhibitor
COX/5-LO-IN-1 is a potent inhibitor targeting cyclooxygenase (COX) and 5-lipoxygenase (5-LO), integral enzymes in the arachidonic acid pathway. This compound demonstrates significant anti-inflammatory and anti-allergic properties, making it a valuable tool for investigating the molecular mechanisms underlying inflammatory and allergic diseases. Its dual inhibition profile supports research into therapeutic strategies for various pathological conditions linked to dysregulated eicosanoid signaling. -
COX Inhibitor
SC58451 is a selective inhibitor of cyclooxygenase-2 (COX-2), known for its potency in downregulating inflammatory pathways. By specifically targeting COX-2, this compound is effective in reducing prostaglandin synthesis, making it valuable for studies related to inflammation and pain management. SC58451 is suitable for research applications in understanding diseases where COX-2 plays a critical role, such as cancer and inflammatory disorders. -
GABAA Receptor Modulator
6-Methoxyflavanone is a flavonoid compound that acts as a positive allosteric modulator of GABAA receptors, specifically enhancing the activity of human recombinant α1β2γ2L and α2β2γ2L subtypes. This compound is capable of crossing the blood-brain barrier and demonstrates key biological activities including anti-anxiety effects, analgesic properties, and relief from neuropathic pain. Additionally, 6-Methoxyflavanone exhibits inhibitory activity towards bitter receptor hTAS2R39 and hTAS2R14, providing a reversible antagonistic effect. Its unique profile makes it a valuable tool for research in neuroscience and pharmacology. -
COX Inhibitor
Inulicin (1-O-Acetylbritannilactone) is a potent inhibitor of cyclooxygenase (COX) enzymes, specifically targeting COX-2 activity. This compound demonstrates significant biological activity by inhibiting lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) as well as the expression of COX-2. Additionally, Inulicin suppresses NF-κB activation and its translocation, making it valuable for research applications related to inflammation and cancer. -
COX Inhibitor
COX-1-IN-3 is a selective inhibitor of cyclooxygenase-1 (COX-1), exhibiting non-steroidal anti-inflammatory properties. This compound is valuable for research focused on inflammation and pain management, as it modulates the biosynthesis of prostaglandins. Its specificity for COX-1 makes it an important tool for studying COX-1-related pathways and associated biological processes. -
COX Inhibitor
(S)-Ketorolac is a nonsteroidal anti-inflammatory drug that primarily functions as an inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes. This compound is characterized by its potent analgesic and anti-inflammatory properties, making it suitable for pain management in various research applications. Its ability to selectively inhibit COX enzymes positions (S)-Ketorolac as a valuable tool in studies focused on inflammatory processes and pain modulation. -
COX Inhibitor
(±)-Naproxen is a non-steroidal anti-inflammatory drug that inhibits both COX-1 and COX-2 enzymes, exhibiting IC50 values of 8.72 μM and 5.15 μM, respectively. This compound is primarily used in research for its potent anti-inflammatory and analgesic properties. It provides valuable insights into the mechanisms of pain relief and inflammation, making it suitable for various studies in pharmacology and biochemistry. -
sEH/COX-1 Inhibitor
PTUPB is a potent dual inhibitor of soluble epoxide hydrolase (sEH) and cyclooxygenase-1 (COX-1), exhibiting IC50 values of 0.9 nM and 1.26 μM, respectively. This compound is relevant for studies investigating the modulation of inflammatory processes, as it effectively interferes with pathways involving arachidonic acid metabolism. PTUPB serves as a valuable research tool for exploring the therapeutic potential of sEH and COX-1 inhibition in various disease models. -
COX/5-LOX Inhibitor
Phenethyl ferulate is a potent inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LOX), displaying IC50 values of 4.35 μM and 5.75 μM, respectively. This compound exhibits significant anti-inflammatory properties, making it a valuable tool for research into inflammation-related pathways. Its ability to modulate these key enzymes positions it as a promising candidate for studies focused on inflammatory diseases and therapeutic interventions. -
COX Inhibitor
4-Methylamino antipyrine is a COX inhibitor derived from the active metabolite of Metamizole, a pyrazolone non-steroidal anti-inflammatory drug (NSAID). It exhibits analgesic and antipyretic activities, making it beneficial for alleviating pain and reducing fever. Although its anti-inflammatory properties are relatively weak, 4-Methylamino antipyrine serves as a valuable tool in pharmacological studies involving pain management and inflammatory responses. -
COX-2/iNOS Inhibitor
α-Chaconine is an inhibitor of COX-2 and iNOS, which demonstrates significant anti-inflammatory activity. It effectively reduces the transcriptional expression of COX-2, IL-1β, IL-6, and TNF-α. Additionally, α-Chaconine suppresses LPS-induced expression of iNOS and COX-2 at both the protein and mRNA levels, along with their promoter activities in RAW 264.7 macrophages. This makes α-Chaconine a valuable reagent for studies focused on inflammation and related signaling pathways. -
COX Inhibitor
Sphondin is a cyclooxygenase (COX) inhibitor that effectively reduces the levels of COX-2 protein and prostaglandin E2 (PGE2) release in A549 cells stimulated by IL-1β. This compound's anti-inflammatory properties make it a valuable tool for research into COX-related pathways and the modulation of inflammatory responses in various cellular models. Sphondin can facilitate investigations into therapeutic strategies for inflammatory diseases. -
5-LOX/COX Inhibitor
FPL 62064 is a potent dual inhibitor of 5-lipoxygenase (5-LOX) and cyclooxygenase (COX), exhibiting IC50 values of 3.5 μM and 3.1 μM, respectively, in RBL-1 cells. This compound demonstrates significant anti-inflammatory activity, making it a valuable tool for research into inflammatory pathways and related diseases. Its dual inhibition of leukotriene and prostaglandin synthesis positions FPL 62064 as a pertinent reagent for studies focusing on inflammation and related therapeutic interventions. -
sPLA2/COX-2 Inhibitor
Alminoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that functions as an inhibitor of secretory phospholipase A2 (sPLA2) and cyclooxygenase-2 (COX-2). This compound exhibits potent anti-inflammatory activity, making it useful in research focused on inflammation and pain modulation. Its dual mechanism of action presents opportunities for investigating pathways involved in inflammatory diseases and related therapeutic interventions. -
COX Antagonist
Sudoxicam is a reversible, orally active cyclooxygenase (COX) antagonist classified as a non-steroidal anti-inflammatory drug (NSAID). It exhibits potent anti-inflammatory, anti-edema, and antipyretic activities, making it useful in various research applications related to inflammatory conditions and pain management. Its mechanism of action positions it as a valuable compound for studies investigating the role of COX enzymes in disease processes. -
COX Inhibitor
Pelubiprofen is an orally active anti-inflammatory agent that inhibits cyclooxygenase (COX) enzyme activity, displaying IC50 values of 10.66 μM for COX-1 and 2.88 μM for COX-2. It demonstrates notable anti-inflammatory and analgesic properties, making it valuable for research in pain management and inflammation pathways. Pelubiprofen can be utilized in studies examining the roles of COX enzymes in various biological processes and diseases. -
COX
Thromboxane B3 is a prostaglandin analog produced via the cyclooxygenase (COX) metabolic pathway from arachidonic acid. It is synthesized in platelets and vascular endothelial cells through the action of COX and thromboxane synthase. Thromboxane B3 has been identified as a product of human platelets when eicosapentaenoic acid is ingested, indicating its role in modulating vascular functions and platelet aggregation. This compound is relevant for research on cardiovascular diseases and inflammatory processes. -
COX Inhibitor
Ketorolac-d5 is a deuterated form of Ketorolac, a non-steroidal anti-inflammatory drug that functions as a nonselective inhibitor of cyclooxygenase (COX). It displays inhibitory potency with IC50 values of 20 nM for COX-1 and 120 nM for COX-2. This compound is widely utilized in pharmacological studies to investigate the biochemical pathways of pain and inflammation, as well as in drug metabolism and pharmacokinetic research. -
COX-2 Inhibitor
EXP3179 is a selective cyclooxygenase-2 (COX-2) inhibitor, notably an intermediate aldehyde metabolite of Losartan. It effectively reduces the expression of COX-2 in endothelial cells, leading to significant anti-inflammatory effects. This compound is useful in research applications focused on inflammation and related signaling pathways. -
COX-II Inhibitor
Tazofelone is a selective cyclooxygenase-II (COX-II) inhibitor that demonstrates significant anti-inflammatory properties. Its bioactivation to sulfoxide and quinol metabolites is primarily facilitated by the CYP3A enzyme system. This compound is utilized in research related to inflammatory bowel disease, providing valuable insights into potential therapeutic approaches. -
COX Inhibitor
Ibuprofen Impurity F is a specific impurity of Ibuprofen, a well-known anti-inflammatory compound that inhibits cyclooxygenase enzymes COX-1 and COX-2. It exhibits inhibitory activity with IC50 values of 13 μM for COX-1 and 370 μM for COX-2. This reagent is valuable for quality control and analytical characterization in pharmaceutical research and development, particularly in the study of non-steroidal anti-inflammatory drugs (NSAIDs). -
COX Inhibitor
Piroxicam cinnamate is a cyclooxygenase (COX) inhibitor with demonstrated anti-inflammatory properties. It is stable under gastric conditions, making it suitable for research applications focused on inflammatory-degenerative osteoarticular diseases, rheumatic disorders, and varicocele-associated oligoasthenospermia. This compound offers significant potential for investigating therapeutic approaches to various inflammatory conditions. -
COX-1 Inhibitor
Valeryl salicylate is a potent and irreversible inhibitor of cyclooxygenase-1 (COX-1). This compound exhibits significant anti-inflammatory activity, making it a valuable tool for research into inflammatory processes. Its mechanism offers insights into the modulation of COX-1 enzyme activity and potential therapeutic applications in inflammatory conditions. -
COX1/2 Inhibitor
4,4'-Dihydroxy-2,6-dimethoxydihydrochalcone is a selective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). This compound demonstrates significant anti-inflammatory properties and is valuable in research aimed at understanding the role of COX enzymes in various disease models. Its application extends to pharmacological studies focused on pain, inflammation, and potential therapeutic interventions. -
COX Inhibitor
Ibuprofen impurity 1 is an impurity of the widely used anti-inflammatory agent ibuprofen, which acts as a dual inhibitor of cyclooxygenase enzymes COX-1 and COX-2, exhibiting IC50 values of 13 μM and 370 μM, respectively. This compound is essential for evaluating the purity and quality of ibuprofen formulations in research. It serves as a valuable tool for studying the pharmacological effects and potential side effects of ibuprofen in various biological assays. -
COX-2 Inhibitor
Robenacoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with potent anti-inflammatory and analgesic properties. It primarily reduces the production of prostaglandins associated with inflammation and pain, making it valuable for research related to inflammatory diseases and pain management. This compound is utilized in studies aiming to elucidate the role of COX-2 in various biological processes and to develop therapeutic strategies targeting inflammation. -
COX-2 Inhibitor
3-Carene is a bicyclic monoterpene that functions as a cyclooxygenase-2 (COX-2) inhibitor. It demonstrates significant anti-inflammatory properties by reducing nociceptive stimulus-induced inflammatory infiltrates and decreasing COX-2 overexpression. Additionally, 3-Carene enhances both the activity and expression of alkaline phosphatase, a crucial early marker of osteoblastic differentiation, making it a valuable compound for research in pain management and bone health. -
COX-2 Inhibitor
Mavacoxib is a selective, oral cyclooxygenase-2 (COX-2) inhibitor, functioning as a long-acting non-steroidal anti-inflammatory drug (NSAID). This compound effectively alleviates pain and inflammation related to degenerative joint disease, particularly in canine subjects. Research applications include studies on inflammation and pain management in veterinary medicine. -
COX-2 Inhibitor
Desmethyl Celecoxib is a selective inhibitor of cyclooxygenase-2 (COX-2) with an IC50 value of 32 nM, demonstrating significant anti-inflammatory activity. As an analog of Celecoxib, this compound serves as a valuable tool in research applications focusing on inflammation and pain pathways. Its potency and specificity make it suitable for studies related to COX-2 mediated processes. -
5-LO/COX Inhibitor
BW 755C is a dual inhibitor of 5-lipoxygenase (5-LO) and cyclooxygenase (COX) enzymes, exhibiting an IC50 of 5 μM for 5-LO. It also demonstrates inhibitory activity against COX-1 and COX-2, with IC50 values of 0.65 and 1.2 μg/mL, respectively. This compound is valuable for research applications involving inflammation and other related pathways. Its ability to concurrently inhibit key lipid mediators makes BW 755C a useful tool in studies focused on arachidonic acid metabolism and signaling pathways. -
COX-2 Inhibitor
Enflicoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), a key enzyme in the inflammatory pathway. This nonsteroidal anti-inflammatory compound exhibits notable anti-inflammatory, analgesic, and antipyretic effects in various animal models. Enflicoxib is valuable for research investigating COX-2-mediated processes and potential therapeutic applications in pain management and inflammation. -
COX-1 Inhibitor
CP-74006 is a selective inhibitor of Cyclooxygenase-1 (COX-1). This compound demonstrates significant anti-inflammatory activity by blocking the conversion of arachidonic acid to prostaglandins, key mediators in the inflammatory response. CP-74006 is utilized in research focusing on inflammation, pain management, and cardiovascular disease, providing valuable insights into COX-1 related biological processes. -
COX inhibitor
2-Chloro-N-(2,6-dimethylphenyl)acetamide is a cyclooxygenase (COX) inhibitor that modulates inflammatory responses by inhibiting the conversion of arachidonic acid to prostaglandins. Its biological activity makes it a valuable tool in research focused on inflammation and pain pathways. This compound is utilized for studying COX-related mechanisms in various biological contexts, potentially aiding in the development of anti-inflammatory therapies. -
COX- 2 Inhibitor
Ocarocoxib is a selective cyclooxygenase-2 (COX-2) inhibitor with an IC50 value of 1.4 μM. By inhibiting COX-2, Ocarocoxib effectively reduces the synthesis of prostaglandins, thereby imparting significant anti-inflammatory effects. This compound is useful for research on inflammation and associated pathological conditions. -
COX-2/5-LOX Inhibitor
Tebufelone is a selective dual inhibitor of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LO). It exhibits significant anti-inflammatory, analgesic, and antipyretic properties, making it useful for research into inflammatory pathways. This compound is valuable for studying the roles of COX-2 and 5-LO in various biological processes and assessing novel therapeutic strategies for inflammatory diseases. -
COX-1 Inhibitor
Teriflunomide impurity 3, also known as 4-Amino-N-(4-trifluoromethylphenyl)benzamide, acts as a selective inhibitor of cyclooxygenase-1 (COX-1) with an IC50 of 30 µM. This compound exhibits significantly lower activity against COX-2, with an IC50 greater than 100 µM. Teriflunomide impurity 3 is valuable for research applications exploring inflammatory pathways and the role of COX-1 in various biological processes. -
COX
ASP6537 is a selective inhibitor of recombinant human cyclooxygenase-1 (rhCOX-1), exhibiting an IC50 value of 0.703 nM. Its potent inhibition of COX-1 makes it a valuable tool for studying the role of prostaglandins in cardiovascular disease research. Researchers can utilize ASP6537 to investigate the effects of COX-1 modulation on cardiovascular pathophysiology. -
iNOS/COX-2 Inhibitor
Rehmapicrogenin is a selective inhibitor of inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2). This compound, derived from the root of Rehmannia glutinosa, demonstrates significant anti-inflammatory properties, making it a valuable tool for research focused on inflammation pathways. Its ability to inhibit pro-inflammatory mediators such as IL-6 further underscores its relevance in studies aimed at understanding and treating inflammatory diseases. -
COX-1/COX-2 Inhibitor
(S)-(+)-Ibuprofen-d3 is a deuterated analog of (S)-(+)-Ibuprofen, targeting the COX-1 and COX-2 enzymes. With IC50 values of 2.1 μM and 1.6 μM, respectively, this compound exhibits significant analgesic, anti-inflammatory, and antipyretic properties. It serves as a valuable tool for studying the pharmacodynamics and mechanisms of nonsteroidal anti-inflammatory drugs (NSAIDs) in various biological research applications. -
COX Inhibitor
Isoxicam is a non-steroidal anti-inflammatory drug (NSAID) that functions as a nonselective inhibitor of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Its primary mechanism involves the inhibition of prostaglandin synthesis, making it effective in reducing inflammation and pain. Isoxicam is commonly utilized in research related to arthritis and other inflammatory conditions, providing valuable insights into the role of COX enzymes in various biological processes. -
COX-2 Inhibitor
Cimicoxib is a selective COX-2 inhibitor that effectively penetrates the blood-brain barrier. It displays significant anti-inflammatory, analgesic, and antipyretic properties by inhibiting the production of thromboxane B2 and prostaglandin E2, with an IC50 of 66 nM against human COX-2. Additionally, Cimicoxib targets CYP2D15, exhibiting an IC50 of 1.6 μM in canines and 0.056 μM in felines. This compound is utilized in research involving inflammatory diseases, osteoarthritis, and perioperative pain management in orthopedic and soft tissue surgeries. -
COX Inhibitor
Naproxen glucuronide, a metabolite of naproxen, functions as a non-selective cyclooxygenase (COX) inhibitor. This compound exhibits significant anti-inflammatory, analgesic, and antipyretic activity, making it useful in the study of pain relief and inflammation pathways. Research applications include examining its metabolic pathways, assessing its efficacy in various inflammatory conditions, and exploring its pharmacokinetic properties in biological systems. -
Dual COX/5-LOX Inhibitor
ER-34122 is a dual inhibitor of cyclooxygenase (COX) and 5-lipoxygenase (5-LO). This compound exhibits significant anti-inflammatory activity, making it valuable for research into inflammation-related pathways. ER-34122 is particularly relevant for studies investigating the interplay between COX and 5-LO pathways in various disease models and therapeutic contexts. -
COX-2 Inhibitor
Apricoxib is a selective inhibitor of cyclooxygenase-2 (COX-2), demonstrating a potent inhibitory effect on PGE2 production with an IC50 of 1.5 nM. This compound exhibits notable biological activities, including anticancer, analgesic, and anti-inflammatory properties. Apricoxib is a valuable tool for research applications focused on inflammation, pain management, and cancer therapeutics. -
COX-2/PGE2 Inducer
Rebamipide-d4 is a deuterium-labeled derivative of Rebamipide, primarily targeting cyclooxygenase-2 (COX-2). This compound induces COX-2 expression and elevates prostaglandin E2 (PGE2) levels, thereby enhancing gastric mucosal defense mechanisms in a COX-2-dependent manner. Rebamipide-d4 is utilized in various research applications focused on gastric protection and the modulation of inflammatory responses. -
Alkaloid
(S)-Laudanosine is an alkaloid with a primary action on the central nervous system and cardiovascular system. It inhibits low-affinity GABA receptors, exhibiting an IC50 value of 10 μM and has the potential to induce seizures, hypotension, and bradycardia. Additionally, (S)-Laudanosine demonstrates analgesic properties through competitive binding to the opioid Mu-1 receptor, with a binding affinity characterized by a Ki value of 2.7 μM. This compound is valuable for research into neurological and cardiovascular functions. -
μ-Opioid Receptor Agoinst/AChE Inhibitor
Eseroline is a potent μ-opioid receptor agonist and a selective, competitive inhibitor of acetylcholinesterase (AChE), with Ki values of 0.1 μM for AChE and 200 μM for butyrylcholinesterase (BuChE). This compound also acts as a nicotinic acetylcholine receptor allosteric enhancing ligand, enhancing acetylcholine signal transduction without directly activating the receptor. Eseroline's neurotoxic effects include cell membrane damage and energy metabolism disruption, making it a valuable tool for investigating Alzheimer's disease pathology and cholinergic signaling. -
P2Y14 Agonist
Uridine 5'-diphosphoglucose disodium is a potent agonist of the P2Y14 receptor, which plays a critical role in the regulation of inflammation and neutrophil polarization in response to ischemic conditions. Secreted by cardiomyocytes, this compound is involved in the synthesis of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in various biological systems. Its ability to modulate inflammatory responses makes Uridine 5'-diphosphoglucose disodium a valuable reagent for studies focused on myocardial infarction and reperfusion-induced inflammation. -
P2Y14R Antagonist
MRS4654 is a potent antagonist of the P2Y14 receptor, with reported inhibitory constants of 15.0 nM for human P2Y14 and 18.6 nM for mouse P2Y14. This compound exhibits significant analgesic and anti-inflammatory properties, making it a valuable tool for investigating pathways involved in pain modulation. MRS4654 is suitable for research applications focused on asthma and neuropathic pain models. -
P2Y14 Receptor Agonist
UDP-Galactose disodium is a potent agonist of the P2Y14 receptor, demonstrating an EC50 of 0.67 μM for the human variant. This compound serves as a substrate for the enzyme beta-1,4 galactosyltransferase V (B4GALT5), playing a critical role in glycosylation processes. Additionally, UDP-Galactose disodium is essential for the biosynthesis of various glycoconjugates that contribute to the surface glycocalyx of Leishmania major, making it valuable for research in cell signaling and pathogen biology.
